Richard Carvajal
Deputy Physician-in-Chief · Zucker School of Medicine at Hofstra/Northwell
Credentials: · · · ·
History
- 2000–2003
Internal Medicine
Research
Safety, activity, and immune correlates of anti-PD-1 antibody in cancer
New England Journal of Medicine · 2012 · 10,404 citations
Journal of Clinical Oncology · 2014 · 1,880 citations
Journal of Clinical Oncology · 2015 · 962 citations
55 papers
- AS
34 papers · 14 as a fellow
29 papers
24 papers
22 papers
20 papers · 2 as a fellow
- SK
19 papers · 4 as a fellow
- MD
17 papers · 1 as a fellow
Grants
- 2021–2022
National Cancer Institute · R21
PI · $126.8K · Medical University of South Carolina
- 2008–2012
Randomized Phase II Study of QS-DG +/- Trivalent Ganglioside Vaccine in Stage IV
National Cancer Institute · R21
Contact PI · $853.5K · Sloan-Kettering Inst Can Research
Clinical trials
- 2019–2020
Nivolumab With Vismodegib in Patients With Basal Cell Nevus Syndrome
Principal investigator · Withdrawn · Phase 2
Columbia University
- 2018–2020
Epacadostat and Pembrolizumab in Patients With GIST
Principal investigator · Terminated · Phase 2
Columbia University
- 2015–2016
Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases
Principal investigator · Terminated · Phase 2
Melissa Burgess, MD
- 2014–2018
Trial of AEB071 in Combination With BYL719 in Patients With Melanoma
Principal investigator · Completed · Phase 1
Columbia University